Thomas W. Beetham's most recent trade in Viridian Therapeutics Inc was a trade of 225,814 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | Thomas W. Beetham | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 225,814 | 225,814 | - | - | Stock Option (Right to Buy) | |
| Viridian Therapeutics Inc | Thomas W. Beetham | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 37,636 | 37,636 | - | - | Restricted Stock Units | |
| Viridian Therapeutics Inc | Thomas W. Beetham | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 23.41 per share. | 27 Sep 2024 | 5,000 | 6,000 (0%) | 0% | 23.4 | 117,050 | Common Stock |
| Kiniksa Pharmaceuticals Lt... | Thomas W. Beetham | EVP & Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2021 | 5,855 | 5,855 | - | - | Restricted Share Units | |
| Kiniksa Pharmaceuticals Lt... | Thomas W. Beetham | EVP & Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2021 | 4,287 | 4,287 | - | - | Restricted Share Units | |
| Kiniksa Pharmaceuticals Lt... | Thomas W. Beetham | EVP & Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2021 | 52,611 | 52,611 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Thomas W. Beetham | EVP & Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2021 | 8,769 | 8,769 | - | - | Restricted Share Units | |
| Kiniksa Pharmaceuticals Lt... | Thomas W. Beetham | EVP & Chief Legal Officer | 03 Feb 2021 | 300,000 | 114,157 | - | - | Class B Common Shares | ||
| Kiniksa Pharmaceuticals Lt... | Thomas W. Beetham | EVP & Chief Legal Officer | 03 Feb 2021 | 300,000 | 300,000 (1%) | 1% | - | Class A Common Shares | ||
| Kiniksa Pharmaceuticals Lt... | Thomas W. Beetham | EVP & Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 22.09 per share. | 03 Feb 2021 | 2,477 | 297,523 (1%) | 0% | 22.1 | 54,717 | Class A Common Shares |
| Kiniksa Pharmaceuticals Lt... | Thomas W. Beetham | EVP & Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2020 | 75,000 | 75,000 | - | - | Share Option |